This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Adverum Biotechnologies Future Growth

Future criteria checks 2/6

Adverum Biotechnologies's earnings are forecast to decline at 2.1% per annum while its annual revenue is expected to grow at 87.4% per year. EPS is expected to grow by 21% per annum.

Key information

-2.1%

Earnings growth rate

20.97%

EPS growth rate

Biotechs earnings growth	25.4%
Revenue growth rate	87.4%
Future return on equity	n/a
Analyst coverage	Good
Last updated	17 Nov 2025

Recent future growth updates

Recent updates

Seeking Alpha • Nov 18

Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients

Summary Adverum Biotechnologies, Inc. achieved positive results from both the LUNA and OPTIC studies, using Ixo-vec for the treatment of patients with wet age-related macular degeneration. The phase 3 ARTEMIS study, using Ixo-vec in combination with prophylactic regimens for the treatment of patients with wet age-related macular degeneration, expected to begin 1st half of 2025. The global age-related macular degeneration market is expected to reach $19.53 billion by 2032; About 10% of all AMD patients have wet age-related macular degeneration. The company had $153 million in cash as of September 30th of 2024; enough cash to fund its operations into the 2nd half of 2025. Read the full article on Seeking Alpha

Analysis Article • Feb 24

We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analysis Article • Sep 07

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Seeking Alpha • Aug 11

Adverum Biotechnologies GAAP EPS of -$0.44 misses by $0.10

Adverum Biotechnologies press release (NASDAQ:ADVM): Q2 GAAP EPS of -$0.44 misses by $0.10. Cash, cash equivalents and short-term investments were $235.8 million as of June 30, 2022, compared to $305.2 million as of December 31, 2021. Adverum expects the June 30, 2022 cash position to fund operations into 2025. Shares -0.66% AH.

Seeking Alpha • Jul 07

Adverum gains 13% to reach three-month high after Truist upgrade

The shares of Adverum Biotechnologies (NASDAQ:ADVM) added ~13% to reach the highest level since March after Truist upgraded the clinical-stage gene therapy company to Buy from Hold noting the prospects for its wet AMD therapy ixo-vec. Wet age-related macular degeneration or wet AMD is the leading cause of blindness in people over the age of 65. The analysts led by Joon Lee cite clarity in the future development of ixo-vec, formerly known as ADVM-022 in wet AMD after the U.S. and EU regulators agreed for a Phase 2 trial for the candidate targeted at the indication. “We view it as a materially derisking event for wAMD and other future ocular indications based on the AAV.7m8 chassis,” the analysts wrote referring to the vector capsid used in the gene therapy candidate. The analysts expect a series of data readouts in 2023 and point out that Adverum (ADVM) has extended its cash runway by one year to 2025 following the restructuring. The price target raised to $4 from $3 is in line with the current average price target for the stock on Wall Street.

Analysis Article • May 12

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analysis Article • Jul 17

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analysis Article • Apr 06

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analysis Article • Feb 13

Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)

We'd be surprised if Adverum Biotechnologies, Inc. ( NASDAQ:ADVM ) shareholders haven't noticed that the President...

Earnings and Revenue Growth Forecasts

NasdaqCM:ADVM - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	N/A	-203	-238	N/A	3
12/31/2026	0	-194	-215	-211	6
12/31/2025	0	-195	-187	-171	6
9/30/2025	N/A	-185	-138	-138	N/A
6/30/2025	1	-169	-132	-131	N/A
3/31/2025	1	-151	-113	-112	N/A
12/31/2024	1	-131	-93	-92	N/A
9/30/2024	1	-119	-86	-86	N/A
6/30/2024	N/A	-119	-89	-88	N/A
3/31/2024	N/A	-120	-93	-92	N/A
12/31/2023	4	-122	-92	-91	N/A
9/30/2023	4	-126	-89	-88	N/A
6/30/2023	4	-133	-97	-96	N/A
3/31/2023	4	-146	-109	-102	N/A
12/31/2022	N/A	-155	-120	-108	N/A
9/30/2022	N/A	-156	-131	-115	N/A
6/30/2022	N/A	-154	-130	-109	N/A
3/31/2022	N/A	-155	-133	-114	N/A
12/31/2021	8	-146	-123	-108	N/A
9/30/2021	8	-149	-116	-104	N/A
6/30/2021	8	-138	-115	-105	N/A
3/31/2021	8	-123	-97	-88	N/A
12/31/2020	N/A	-118	-91	-79	N/A
9/30/2020	N/A	-99	-91	-72	N/A
6/30/2020	0	-87	-77	-55	N/A
3/31/2020	0	-73	-71	-50	N/A
12/31/2019	0	-64	-68	-49	N/A
9/30/2019	0	-61	-58	-47	N/A
6/30/2019	1	-66	N/A	-54	N/A
3/31/2019	1	-70	N/A	-54	N/A
12/31/2018	2	-73	N/A	-54	N/A
9/30/2018	2	-72	N/A	-53	N/A
6/30/2018	2	-65	N/A	-47	N/A
3/31/2018	2	-57	N/A	-47	N/A
12/31/2017	2	-56	N/A	-45	N/A
9/30/2017	2	-64	N/A	-42	N/A
6/30/2017	2	-64	N/A	-41	N/A
3/31/2017	2	-114	N/A	-38	N/A
12/31/2016	1	-114	N/A	-38	N/A
9/30/2016	2	-105	N/A	-39	N/A
6/30/2016	2	-105	N/A	-39	N/A
3/31/2016	2	-53	N/A	-40	N/A
12/31/2015	2	-47	N/A	-35	N/A
9/30/2015	2	-44	N/A	-31	N/A
6/30/2015	1	-38	N/A	-27	N/A
3/31/2015	1	-36	N/A	-12	N/A
12/31/2014	1	-29	N/A	-6	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ADVM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ADVM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ADVM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ADVM's revenue (87.4% per year) is forecast to grow faster than the US market (10.7% per year).

High Growth Revenue: ADVM's revenue (87.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ADVM's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/12/10 23:07
End of Day Share Price	2025/12/08 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Adverum Biotechnologies, Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Graig Suvannavejh	Goldman Sachs
Biren Amin	Jefferies LLC
Mani Foroohar	Leerink Partners LLC

This company has been acquired

Adverum Biotechnologies Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus revenue estimates fall by 99%

Price target decreased by 44% to US$11.00

Consensus EPS estimates fall by 11%

Price target decreased by 24% to US$19.75

Price target decreased to US$3.67

Price target decreased to US$3.67

Recent updates

Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) dropped from Russell Microcap Growth Index

Consensus revenue estimates fall by 99%

New major risk - Financial position

Price target decreased by 44% to US$11.00

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Adverum Biotechnologies, Inc. (NasdaqCM:ADVM) for $80.2 million.

Consensus EPS estimates fall by 11%

Adverum Biotechnologies, Inc. Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-Cov for Wet Age-Related Macular Degeneration

Adverum Biotechnologies, Inc. announced that it has received $10 million in funding from Frazier Life Sciences Management, LP

Price target decreased by 24% to US$19.75

Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) dropped from Russell 3000 Value Index

Adverum Biotechnologies, Inc., Annual General Meeting, Jun 17, 2025

Adverum Biotechnologies, Inc. Auditor Raises 'Going Concern' Doubt

Adverum Biotechnologies, Inc. announced delayed annual 10-K filing

Adverum Biotechnologies, Inc. Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

Adverum Biotechnologies Announces Positive 52-Week Luna and 4-Year Optic Results, and Provides Key Pivotal Program Design Elements

Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients

Adverum Biotechnologies, Inc. Appoints Jason L. Mitchell as Chief Commercial Officer

Adverum Biotechnologies Announces Fda Regenerative Medicine Advanced Therapy (Rmat) Designation Granted for Ixo-Vec for the Treatment of Wet Amd

Adverum Biotechnologies, Inc. Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies, Inc., Annual General Meeting, Jun 17, 2024

Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD

Adverum Biotechnologies, Inc. Announces Stipulation and Agreement of Settlement

Adverum Biotechnologies, Inc. announced that it expects to receive $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee

Adverum Biotechnologies Receives a Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

Adverum Biotechnologies, Inc. Appoints C. David Nicholson to the Board of Directors

Adverum Biotechnologies, Inc. Announces Positive Aflibercept Protein Level Data from the Luna Phase 2 Trial

Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer

Adverum Biotechnologies, Inc. Completes Enrollment of Phase 2 LUNA Trial in Wet AMD

Adverum Biotechnologies Receives Nasdaq Notice on Regained Compliance with Minimum Bid Price Requirement

Adverum Biotechnologies, Inc. Announces Resignation of Richard Beckman as Chief Medical Officer

Adverum Biotechnologies, Inc. Receives Approval from the Listing Qualifications Department of Nasdaq to Transfer the Listing of Common Stock from Nasdaq Global Market to Nasdaq Capital Market

Adverum Biotechnologies, Inc. Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual Meeting

We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Price target decreased to US$3.67

Price target decreased to US$3.67

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Adverum Biotechnologies GAAP EPS of -$0.44 misses by $0.10

Price target increased to US$4.33

Adverum gains 13% to reach three-month high after Truist upgrade

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Price target increased to US$4.33

High number of new directors

Independent Director recently sold US$109k worth of stock

Price target increased to US$4.33

Chief Business Officer & Acting CFO Christopher DeRespino has left the company

Price target decreased to US$3.57

Consensus revenue estimates increase to US$6.00m

Consensus forecasts updated

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Price target decreased to US$17.11

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Independent Chairman recently bought US$99k worth of stock

New 90-day low: US$10.55

Analysts lower revenue estimates to US$230.0k

Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)

New 90-day high: US$14.36

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics